A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Mixed Lineage Acute Leukemia · Mixed Phenotype Acute Leukemia · Acute Leukemia of Ambiguous Lineage
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.6
2 insiders sold shares within a month
Since Jun 1, 2026 · was worth 10, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 447 (planned)
- Started
- Nov 5, 2019
- Main results expected
- Dec 15, 2027
- Fully finished
- Dec 15, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of participants with dose-limiting toxicities (DLTs) (Phase 1)
Measured over: Approximately 1 year
Number of participants with treatment-emergent adverse events (TEAEs) (Phase 1)
Measured over: Approximately 1 year
Cmax (Phase 1)
Measured over: Approximately 1 year
Tmax (Phase 1)
Measured over: Approximately 1 year
AUC0-t (Phase 1)
Measured over: Approximately 1 year
CR+CRh rate (Phase 2 [Cohorts 2A-2C])
Measured over: Approximately 3 years
Number of participants with TEAEs (Phase 2 [Cohorts 2A-2C])
Measured over: Approximately 3 years
Cmax (Phase 2 [Cohort 2D])
Measured over: Approximately 3 years
AUC0-tau (Phase 2 [Cohort 2D])
Measured over: Approximately 3 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.6, since 2026-06-01, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04065399 · record last updated 2026-10-09 · checked 2026-11-09 15:47 UTC